Zhang W, Sunami K, Liu S, Triana D, Tachrim Z, Kikuchi R
Sci Rep. 2025; 15(1):3110.
PMID: 39856167
PMC: 11760887.
DOI: 10.1038/s41598-025-87070-z.
Bearden A, Stewart E, Casher C, Shaddix M, Nobles A, Mockett R
Int J Mol Sci. 2024; 25(21).
PMID: 39519056
PMC: 11547029.
DOI: 10.3390/ijms252111504.
He Y, Xu W, Xiao Y, Huang H, Gu D, Ren S
Signal Transduct Target Ther. 2022; 7(1):198.
PMID: 35750683
PMC: 9232569.
DOI: 10.1038/s41392-022-01042-7.
Pungsrinont T, Kallenbach J, Baniahmad A
Int J Mol Sci. 2021; 22(20).
PMID: 34681745
PMC: 8538152.
DOI: 10.3390/ijms222011088.
Cantrell W, Huang Y, Menchaca A, Kulik G, Welker M
Molecules. 2018; 23(7).
PMID: 30036994
PMC: 6100554.
DOI: 10.3390/molecules23071791.
Synthesis and PI 3-Kinase Inhibition Activity of Some Novel 2,4,6-Trisubstituted 1,3,5-Triazines.
Nelson Jr R, Schronce T, Huang Y, Albugami A, Kulik G, Welker M
Molecules. 2018; 23(7).
PMID: 29973512
PMC: 6100378.
DOI: 10.3390/molecules23071628.
Strategies for the Synthesis of the Halenaquinol and Xestoquinol Families of Natural Products.
Schwarzwalder G, Vanderwal C
European J Org Chem. 2018; 2017(12):1567-1577.
PMID: 29527124
PMC: 5841243.
DOI: 10.1002/ejoc.201601418.
Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions.
Jackson P, Widen J, Harki D, Brummond K
J Med Chem. 2016; 60(3):839-885.
PMID: 27996267
PMC: 5308545.
DOI: 10.1021/acs.jmedchem.6b00788.
Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment.
Castel P, Toska E, Zumsteg Z, Javier Carmona F, Elkabets M, Bosch A
Mol Cell Oncol. 2016; 1(3):e963447.
PMID: 27308344
PMC: 4904898.
DOI: 10.4161/23723548.2014.963447.
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Jimeno A, Bauman J, Weissman C, Adkins D, Schnadig I, Beauregard P
Oral Oncol. 2015; 51(4):383-8.
PMID: 25593016
PMC: 4857706.
DOI: 10.1016/j.oraloncology.2014.12.013.
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.
Bowles D, Senzer N, Hausman D, Peterson S, Vo A, Walker L
Invest New Drugs. 2014; 32(6):1197-203.
PMID: 24916771
DOI: 10.1007/s10637-014-0124-3.
Molecular insights into the membrane-associated phosphatidylinositol 4-kinase IIα.
Zhou Q, Li J, Yu H, Zhai Y, Gao Z, Liu Y
Nat Commun. 2014; 5:3552.
PMID: 24675427
PMC: 3974213.
DOI: 10.1038/ncomms4552.
Pharmacologic profiling of phosphoinositide 3-kinase inhibitors as mitigators of ionizing radiation-induced cell death.
Lazo J, Sharlow E, Epperly M, Lira A, Leimgruber S, Skoda E
J Pharmacol Exp Ther. 2013; 347(3):669-80.
PMID: 24068833
PMC: 3836314.
DOI: 10.1124/jpet.113.208421.
A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours.
Bowles D, Ma W, Senzer N, Brahmer J, Adjei A, Davies M
Br J Cancer. 2013; 109(5):1085-92.
PMID: 23942080
PMC: 3778312.
DOI: 10.1038/bjc.2013.474.
Improved synthesis of 17β-hydroxy-16α-iodo-wortmannin, 17β-hydroxy-16α-iodoPX866, and the [(131)I] analogue as useful PET tracers for PI3-kinase.
Sun D, Prasad B, Schuber Jr P, Peng Z, Maxwell D, Martin D
Bioorg Med Chem. 2013; 21(17):5182-7.
PMID: 23859776
PMC: 3960976.
DOI: 10.1016/j.bmc.2013.06.036.
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.
Keysar S, Astling D, Anderson R, Vogler B, Bowles D, Morton J
Mol Oncol. 2013; 7(4):776-90.
PMID: 23607916
PMC: 3760013.
DOI: 10.1016/j.molonc.2013.03.004.
Molecular targets and mechanisms of radiosensitization using DNA damage response pathways.
Raleigh D, Haas-Kogan D
Future Oncol. 2013; 9(2):219-33.
PMID: 23414472
PMC: 3635474.
DOI: 10.2217/fon.12.185.
Synthesis of 1,2,4-triazines and the triazinoisoquinolinedione DEF ring system of noelaquinone.
Cao L, Maciejewski J, Elzner S, Amantini D, Wipf P
Org Biomol Chem. 2012; 10(30):5811-4.
PMID: 22473572
PMC: 3535313.
DOI: 10.1039/c2ob25353d.
Total synthesis of (-)-CP2-disorazole C1.
Hopkins C, Schmitz J, Chu E, Wipf P
Org Lett. 2011; 13(15):4088-91.
PMID: 21739942
PMC: 3160746.
DOI: 10.1021/ol2015994.
Regioselective Palladium-Catalyzed Cross-Coupling Reactions of 2,4,7-Trichloroquinazoline.
Wipf P, George K
Synlett. 2010; 2010(4):644-648.
PMID: 21116479
PMC: 2992347.
DOI: 10.1055/s-0029-1219391.